Haas NB - Search Results

1

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F Jr, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, Plimack ER, Choueiri TK, Uzzo R, Apolo AB. Agrawal S, et al. Among authors: haas nb. JAMA Oncol. 2020 Jan 1;6(1):133-141. doi: 10.1001/jamaoncol.2019.4117. JAMA Oncol. 2020. PMID: 31750870 Free PMC article.

2

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician.

Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg RE, Kolenko V. Uzzo RG, et al. Urol Clin North Am. 2003 Aug;30(3):423-36. doi: 10.1016/s0094-0143(03)00021-1. Urol Clin North Am. 2003. PMID: 12953746 Review.

3

Adjuvant therapy for high-risk renal cell carcinoma patients.

Kunkle DA, Haas NB, Uzzo RG. Kunkle DA, et al. Among authors: haas nb. Curr Urol Rep. 2007 Jan;8(1):19-30. doi: 10.1007/s11934-007-0017-5. Curr Urol Rep. 2007. PMID: 17239313 Review.

4

Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.

Haas NB, Uzzo RG. Haas NB, et al. Curr Treat Options Oncol. 2007 Jun;8(3):211-26. doi: 10.1007/s11864-007-0031-3. Curr Treat Options Oncol. 2007. PMID: 17712534 Review.

5

Targeted therapies for kidney cancer in urologic practice.

Haas NB, Uzzo RG. Haas NB, et al. Urol Oncol. 2007 Sep-Oct;25(5):420-32. doi: 10.1016/j.urolonc.2007.05.009. Urol Oncol. 2007. PMID: 17826664 Review.

6

Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.

Uzzo RG, Haas NB, Crispen PL, Kolenko VM. Uzzo RG, et al. Among authors: haas nb. Cancer. 2008 Apr 15;112(8):1660-71. doi: 10.1002/cncr.23318. Cancer. 2008. PMID: 18278811 Free article. Review.

7

Adjuvant therapy for renal cell carcinoma.

Haas NB, Uzzo R. Haas NB, et al. Curr Oncol Rep. 2008 May;10(3):245-52. doi: 10.1007/s11912-008-0037-4. Curr Oncol Rep. 2008. PMID: 18765155 Review.

8

Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.

Smaldone MC, Fung C, Uzzo RG, Haas NB. Smaldone MC, et al. Among authors: haas nb. Hematol Oncol Clin North Am. 2011 Aug;25(4):765-91. doi: 10.1016/j.hoc.2011.06.002. Hematol Oncol Clin North Am. 2011. PMID: 21763967 Review.

9

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Choueiri TK, et al. Among authors: haas nb. J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3. J Clin Oncol. 2013. PMID: 23213094 Free PMC article. Clinical Trial.

10

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. Plimack ER, et al. Among authors: haas nb. Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27. Oncologist. 2014. PMID: 24674872 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters